

REMARKS

Applicants hereby elect the alpha-2-adrenergic agonist brimonidine and the trefoil factor family peptide TFF1. Claims 1 – 42 read on the elected species.

Claims 7 – 8 and 18 – 42 are cancelled.

Applicants respectfully traverse the rejection. In order to properly make a restriction requirement, under PCT Rules 13.1 and 13.2, the claims in Groups I and II must lack unity of invention. The Examiner states that Groups I - II do not relate to a single inventive concept because the product is not a contribution over the prior art citing WO 2003045332 as teaching the combination of trefoil peptides and an alpha-2 agonist. Applicants respectfully disagree that such a teaching is made in WO 2003045332. Applicants hereby request withdrawal of the restriction requirement.

Please charge Deposit Account 01-0885 for the extension fees and any other fees due in this case. The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment and any other fees due in this case to Deposit Account No. 01-0885.

Respectfully submitted,

/John E. Wurst/

Date: July 14, 2008

John E. Wurst
Registration No. 40,283
Telephone: 714/246-5475